Regulatory Framework for Medical Devices in India: Structure, Compliance & Recent Updates
Abstract
India’s medical device sector is undergoing rapid transformation driven by regulatory reforms, increased global participation, and a strong push toward quality and patient safety. The regulatory framework, primarily governed by the Medical Devices Rules (MDR), 2017 under the Drugs and Cosmetics Act, 1940, has evolved into a structured, risk-based, and increasingly digitized system. This article provides a comprehensive overview of the regulatory architecture, compliance requirements, and recent updates shaping India’s medical device ecosystem.
1. Introduction
India represents one of the fastest-growing medical device markets globally. To ensure safety, quality, and efficacy, medical devices are regulated under the Drugs and Cosmetics Act, 1940 and the Medical Devices Rules, 2017 (MDR 2017).
The Central Drugs Standard Control Organization (CDSCO) serves as the national regulatory authority, overseeing approvals, licensing, and compliance.
2. Regulatory Structure in India
2.1 Governing Framework
The regulatory system is structured under:
- Drugs and Cosmetics Act, 1940
- Medical Devices Rules, 2017
- Amendments and notifications issued by CDSCO
- The MDR 2017 provides a comprehensive framework covering manufacture, import, sale, and distribution of medical devices.
2.2 Regulatory Authorities
India follows a dual regulatory model:
| Authority | Role |
|---|---|
| CDSCO (Central Licensing Authority) | Import licenses, high-risk devices (Class C & D), clinical investigations |
| State Licensing Authority (SLA) | Manufacturing and sale of low-to-moderate risk devices (Class A & B) |
For example, CDSCO regulates import and high-risk manufacturing, while states handle lower-risk categories.
2.3 Risk-Based Classification
Medical devices are classified into four categories:
| Class | Risk Level |
|---|---|
| Class A | Low risk |
| Class B | Low-moderate risk |
| Class C | Moderate-high risk |
| Class D | High risk |
This classification aligns with global frameworks such as IMDRF and forms the basis for regulatory controls.
3. Regulatory Pathways & Compliance Requirements
3.1 Licensing Requirements
Different licenses are required depending on activity:
- Import License: MD-14 (application) ? MD-15 (approval)
- Manufacturing License: MD-7/MD-8 ? MD-9/MD-10
- Test License: MD-16 ? MD-17
- As of October 2023, most regulated devices require licensing prior to import or sale.
3.2 Key Documentation
Applicants must submit:
- Device Master File (DMF)
- Plant Master File (PMF)
- Clinical evaluation/performance data
- Quality Management System documentation
- Foreign manufacturers must appoint an Authorized Indian Agent for regulatory submissions.
3.3 Quality & Compliance Requirements
Key compliance elements include:
- Adherence to MDR schedules (technical, clinical, labeling)
- Post-market surveillance (PMS)
- Vigilance reporting
- Periodic safety updates
- While ISO 13485 is widely accepted, it is not always mandatory but strengthens compliance credibility.
3.4 In-Vitro Diagnostics (IVDs)
IVDs are regulated similarly to drugs under the Act, with specific licensing and evaluation requirements. CDSCO directly regulates higher-risk IVDs (Class C & D).
4. Recent Regulatory Updates (2024–2026)
4.1 Expansion of Regulatory Scope
India has transitioned toward regulating all medical devices, eliminating earlier distinctions between notified and non-notified devices.
4.2 Risk Classification Updates (2025)
CDSCO proposed updates to risk classification across several device categories, including cardiovascular and radiology devices, aligning more closely with international standards.
4.3 Digitalization & Process Efficiency
- Increased use of online portals (e.g., SUGAM)
- Streamlined application and approval processes
- Improved transparency through FAQs and guidance updates
- Regulatory reforms aim to create a predictable and digitized ecosystem.
4.4 CDSCO Addendums & Clarifications (2025)
Multiple FAQ addendums clarified:
- Licensing procedures
- Labelling requirements
- Post-approval changes
- Software-based medical device classification
- These updates significantly improve regulatory clarity and consistency.
4.5 Software & AI Regulation
Draft guidance for Software as a Medical Device (SaMD) introduces:
- Minor vs major change categorization
- Reporting requirements for updates
- Lifecycle-based regulatory oversight
4.6 Draft Amendments to MDR (2025)
Recent draft amendments aim to:
- Strengthen compliance for Class A manufacturers
- Enhance testing and laboratory requirements
- Improve oversight of importers and foreign manufacturers
5. Challenges in the Indian Regulatory Landscape
Despite progress, challenges remain:
- Evolving regulatory interpretations
- Capacity constraints at state levels
- Alignment with global regulatory frameworks
- Compliance burden for SMEs and startups
6. Opportunities & Future Outlook
India’s regulatory environment is moving toward:
- Global harmonization (IMDRF alignment)
- Increased digital regulation
- Stronger post-market surveillance systems
- Growth in domestic manufacturing (Make in India)
The regulatory ecosystem is expected to become more robust, transparent, and innovation-friendly.
7. Conclusion
India’s medical device regulatory framework has evolved into a structured, risk-based system under MDR 2017. Continuous updates, digitalization, and global alignment are transforming the regulatory landscape. While compliance requirements are becoming more stringent, they are also enhancing product quality, patient safety, and market credibility.
References
- CDSCO – Medical Devices Rules, 2017
- CDSCO – Medical Device & Diagnostics Overview
- CDSCO – Regulatory Structure Overview
- CDSCO Guidance Documents (2024 updates)
- Asia Actual – Medical Device Registration & Import Rules
- Cliniexperts – Import Licensing Process (2026)
- Morulaa – CDSCO FAQs & Addendums (2025)
- Asia Actual – Risk Classification Updates (2025)
- Pacific Bridge Medical – Regulatory Update (2025)
- Nishith Desai Associates – Regulatory Wrap 2025/2026
- NextGen MedTech – MDR Draft Amendments (2025)
